Our Work in Dermatology
Targeted biologics, the recent emergence of innovative new oral therapies, and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.
Atopic Dermatitis, Psoriasis
Board of Advisors
The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with diseases in dermatology and those who are close to them.
Spherix Global Insights Reports Sun Dermatology’s Ilumya Faces Challenges in A Crowded Psoriasis Market – December 5, 2018
Spherix Global Insights’ Annual Update of the Psoriasis Switching Market Reveals Significant Gains for Janssen’s Tremfya, Much to the Detriment of Sister-Brand Stelara – November 20, 2018
Sanofi/Regeneron’s Dupixent Continues to Flourish as the Only Atopic Dermatitis Game in Town, but US Dermatologists Identify a Gap Between Current Patients and Candidates for Treatment – November 7, 2018
Fall Clinical Dermatology Conference